Open AccessMortality in a Cohort of HIV-Infected Adults Started on a Protease Inhibitor-Containing Therapy
Author(s) -
Charlotte Lewden,
François Raffi,
Geneviève Chêne,
Alain Sobel,
Catherine Leport
Publication year - 2001
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/00126334-200104150-00013
Subject(s) - medicine , cohort , mortality rate , population , confidence interval , protease inhibitor (pharmacology) , cohort study , standardized mortality ratio , human immunodeficiency virus (hiv) , demography , antiretroviral therapy , immunology , viral load , environmental health , sociology
Death rates in the APROCO cohort of 1,157 HIV-1 infected adults starting for the first time a protease inhibitor-containing therapy were standardized to the 1996 French general population mortality rates stratified by age and gender. Median follow-up was 23 months and mortality rate was 2.2% person-years (95% confidence interval [CI] = 1.6-2.9). Overall mortality was 7.8 times higher than in the general population (95% CI = 5.7-10.4), 4.7 in men and 19.5 in women. Among the 144 patients considered complete responders, the death rate was 1.2% person-years (95% CI = 0.2-3.5) and mortality remained 5.1 times higher (95% CI = 1.0-14.9) than in the general population. Failure of treatment, long-term adverse effects, or less favorable socio-demographic status could explain these trends.